anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
General: Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurologic manifestations remain progressive.

There is a potential danger in administering folic acid to patients with undiagnosed anemia, since folic acid may obscure the diagnosis of pernicious anemia by alleviating the hematologic manifestations of the disease while allowing the neurologic complications to progress. This may result in severe nervous system damage before the correct diagnosis is made. Adequate doses of vitamin B12 may prevent, halt, or improve the neurologic changes caused by pernicious anemia.

Drug Interactions: There is evidence that the anticonvulsant action of phenytoin is antagonized by folic acid. A patient whose epilepsy is completely controlled by phenytoin may require increased doses to prevent convulsions if folic acid is given. Folate deficiency may result from increased loss of folate, as in renal dialysis and/or interference with metabolism (e.g., folic acid antagonists such as methotrexate); the administration of anticonvulsants, such as phenytoin, primidone, and barbiturates, alcohol consumption and, especially, alcoholic cirrhosis; and the administration of pyrimethamine and nitrofurantoin.

False low serum and red cell folate levels may occur if the patient has been taking antibiotics, such as tetracycline, which suppress the growth of Lactobacillus casei.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals to evaluate carcinogenic potential and studies to evaluate the mutagenic potential or effect on fertility have not been conducted.

Pregnancy - Teratogenic Effects - Pregnancy Category A. Folic acid is usually indicated in the treatment of megaloblastic anemias of pregnancy. Folic acid requirements are markedly increased during pregnancy, and deficiency will result in fetal damage. See INDICATIONS AND USAGE.

Studies in pregnant women have not shown that folic acid increases the risk of abnormalities if administered during pregnancy. If the drug is used during pregnancy, the possibility of fetal harm appears remote. Because studies cannot rule out the possibility of harm, however, folic acid should be used during pregnancy only if clearly needed.

Nursing Mothers: Folic acid is excreted in the milk of lactating mothers. During lactation, folic acid requirements are markedly increased; however, amounts present in human milk are adequate to fulfill infant requirements, although supplementation may be needed in low-birth-weight infants, in those who are breast-fed by mothers with folic acid deficiency (50 μg daily), or in those with infections or prolonged diarrhea.
The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and Respiratory diseases. Compounds of the invention display soft drug characteristics, i.e. they are rapidly inactivated upon entry in the systemic circulation. Therefore, they allow for reduced systemic exposure to functionally active ROCK inhibitors.
Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week ("A time when I felt stressed was ..." ) in order to help identify experiences for discussion in session. Participants will be informed that the control condition is supportive and non-directive, and that providers will not engage in problem-solving. Providers will be taught to use reflective listening, clarification, empathy, and validation. The control consists of 12 weekly sessions delivered via telephone or video.
FIELD: genetic engineering, medicine, pharmacy. SUBSTANCE: invention relates to agents of genetic therapy. Invention proposes compatible two-component system. The first component comprises gene construction encoding cell-recognizing radical and representing anti-CEA antibody and heterologous enzyme carboxypeptidase activating drug. The second component represents prodrug transforming to cytotoxic drug by enzyme carboxypeptidase. Prodrug is taken among group representing N-{4-[N,N-bis-(2-iodoethyl)amino]phenoxy- carbonyl} -L-glutamic acid, gamma-(3,5-dicarboxy)anilide N-{4-[N,N-bis-(2-chloroethyl)amino] - phenoxycarbonyl}-L-glutamic acid or their pharmaceutically acceptable salts. Except for, invention proposes method for delivery of cytotoxic drug to designation point providing administration to the mammal-host of the first component of system and the following administration to the host the second component. Proposed invention allows carrying out the more selective gene-directed enzymatic prodrug therapy and to reduce undesirable effect in normal tissues in the case of mistaken activation of prodrug. Invention can be used in medicine for carrying out antitumor gene-directed enzymatic prodrug therapy. EFFECT: valuable medicinal properties of system, enhanced effectiveness of drug delivery. 9 cl, 6 dwg, 23 ex
The invention provides an attenuation Salmonella typhimurium S116. The attenuation Salmonella typhimurium S116 has no rfbK or cpsG genes. The classification and name of the attenuation strain is Salmonella typhimurium S116, the attenuation Salmonella typhimurium S116 is preserved in the China Center for Type Culture Collection, the preservation number is CCTCC M 2015635, and the preservation date is October 23rd, 2015. The invention further provides a construction method of the attenuation Salmonella typhimurium. The construction method comprises the following steps that a suicide plasmid mediated homologous recombination method is utilized for knocking rfbK or rfbM genes and cpsG or cpsB genes out of attenuation Salmonella typhimurium bacterial genomes, and a mutant strain without rfbK or rfbM genes and cpsG or cpsB genes is obtained. The invention further provides application of the attenuation Salmonella typhimurium S116 in vaccines.
Quantifying skeletal muscle size is necessary to identify those at risk for conditions that increase frailty, morbidity, and mortality, as well as decrease quality of life. Although muscle strength, muscle quality, and physical performance have been suggested as important assessments in the screening, prevention, and management of sarcopenic and cachexic individuals, skeletal muscle size is still a critical objective marker. Several techniques exist for estimating skeletal muscle size; however, each technique presents with unique characteristics regarding simplicity/complexity, cost, radiation dose, accessibility, and portability that are important factors for assessors to consider before applying these modalities in practice. This narrative review presents a discussion centred on the theory and applications of current non-invasive techniques for estimating skeletal muscle size in diverse populations. Common instruments for skeletal muscle assessment include imaging techniques such as computed tomography, magnetic resonance imaging, peripheral quantitative computed tomography, dual-energy X-ray absorptiometry, and Brightness-mode ultrasound, and non-imaging techniques like bioelectrical impedance analysis and anthropometry. Skeletal muscle size can be acquired from these methods using whole-body and/or regional assessments, as well as prediction equations. Notable concerns when conducting assessments include the absence of standardised image acquisition/processing protocols and the variation in cut-off thresholds used to define low skeletal muscle size by clinicians and researchers, which could affect the accuracy and prevalence of diagnoses. Given the importance of evaluating skeletal muscle size, it is imperative practitioners are informed of each technique and their respective strengths and weaknesses.
TACT3a is a double blind, placebo-controlled, randomized trial to test a novel therapy, edetate disodium-based chelation of environmentally acquired toxic metals, to reduce cardiovascular events including amputation in high-risk diabetic patients.

The study plans to enroll 50 patients with diabetes and critical limb ischemia (CLI) to prevent the major cardiovascular endpoints of major amputation, coronary revascularization, stroke, Myocardial Infarction (MI), or death (all-cause) during an average 1.25 years of follow-up. Patients will be randomly assigned to chelation or placebo with a 3:2 (30 active, 20 placebo) allocation ratio. Treatment will consist of 40 active or placebo infusions over 30 weeks. Active therapy will be the same edetate disodium-based infusion used safely and successfully in a previous published study, Trial to Assess Chelation Therapy (TACT). Baseline and post infusion urine metals will be collected. Following the final infusion, patients will be contacted quarterly until the end of the study.
An information processing system for selecting and providing a product for skin for each user, said system being equipped with: a user terminal of the user; a server for managing user information pertaining to a plurality of users and product information pertaining to a plurality of products; an analyst terminal of an analyst who analyzes biological information pertaining to the skin of the user and provided by said user; and a selector terminal of a selector who selects a product for the skin of the user. A control unit of the analyst terminal associates biological analysis information expressing the analysis results of the biological information with user identification information which identifies the user, and transmits the same to the server. A control unit of the server transmits the received biological analysis information to the user terminal of the user which corresponds to the user identification information. A control unit of the selector terminal associates skin analysis information, which expresses analysis results regarding the state of the skin of the user according to a measurement device or visual observation, with the user identification information, and transmits the same to the server. A control unit of the user terminal transmits a product selection request, along with the user identification information, to the selector terminal. Upon receiving the selection request, the control unit of the selector terminal receives the skin analysis information, which corresponds to the user identification information, selects one or more products from the plurality of products on the basis of the skin analysis information and requested information pertaining to the product which is received from the user terminal or inputted into the selector terminal on the basis of a conversation with the user, and transmits, to the server, a shipping request requesting that the selected product is shipped to the user.
The invention discloses a medicine for treating Ankylosing Spondylitis (AS), which is an over-the-counter medicine for orthopedics and lumbar pain. Can be used for treating ankylosing spondylitis and lumbago. The invention is composed of 31 traditional Chinese medicines such as radix polygoni multiflori preparata, salvia miltiorrhiza bunge and the like, and is processed to prepare capsules, tablets or granules for oral administration, and the medicine has mild property and no toxic or side effect. The AS patients have the lesion part on the spine and may involve the joints of the four limbs. The medicine uses the exquisite traditional Chinese medicine to go deep into the spinal column marrow, and uses the grass, stem, branch and vine to reach the limbs, which is not good enough, and has more specific efficacy of the medicine for promoting blood circulation to remove blood stasis, reducing phlegm and dredging collaterals. Can quickly control the progress of the disease course, relieve pain instantly, prevent joint damage, reduce disability rate, does not influence male fertility, and has safety, special effect and low cost. After the patient takes the medicine for one week, the curative effect is obvious, and the patient with the late period of bone destruction can also recover, thereby solving the problem that the AS treatment at present has no specific medicine. It also has good therapeutic effect on rheumatism, chronic lumbar muscle strain, and prolapse of lumbar intervertebral disc.
The invention discloses a medicinal composition for curing hemorrhoids, which is a compound preparation prepared by mixing policresulen and cinchocaine hydrochloride serving as active ingredients, and pharmaceutically acceptable auxiliary materials serving as carriers. The weight of the policresulen in medicinal composition accounts for 3 to 10 percent of the total weight of the composition, and the weight of the cinchocaine hydrochloride accounts for 0.1 to 0.8 percent of the total weight of the composition. The invention also discloses a preparation method of the medicinal composition for curing the hemorrhoid. The policresulen serving as a main active material has the effects of stopping bleeding, converging, regenerating epithelium and sterilizing to make necrotic tissues coagulated and separated so as to quickly clean wounds. Meanwhile, due to the adoption of the composition, strong reactive contrafluxion is generated so as to promote the tissues to regenerate. The medicinal composition carries out local anesthesia by adopting the quick-acting cinchocaine hydrochloride for suppressing pain of wounds. The medicinal composition is prepared into an external preparation, which comprises suppository, ointments and the like. The medicinal composition is suitable for curing hemorrhoids, anal fissure and rhagadia, pruritus ani and the like.
The BAF chromatin remodeler regulates lineage commitment including cranial neural crest cell (CNCC) specification. Variants in BAF subunits cause Coffin-Siris syndrome (CSS), a congenital disorder characterized by coarse craniofacial features and intellectual disability. Approximately 50% of individuals with CSS harbor variants in one of the mutually exclusive BAF subunits, ARID1A/ARID1B. While Arid1a deletion in mouse neural crest causes severe craniofacial phenotypes, little is known about the role of ARID1A in CNCC specification. Using CSS-patient-derived ARID1A+/- induced pluripotent stem cells to model CNCC specification, we discovered that ARID1A-haploinsufficiency impairs epithelial-to-mesenchymal transition (EMT), a process necessary for CNCC delamination and migration from the neural tube. Furthermore, wild-type ARID1A-BAF regulates enhancers associated with EMT genes. ARID1A-BAF binding at these enhancers is impaired in heterozygotes while binding at promoters is unaffected. At the sequence level, these EMT enhancers contain binding motifs for ZIC2, and ZIC2 binding at these sites is ARID1A-dependent. When excluded from EMT enhancers, ZIC2 relocates to neuronal enhancers, triggering aberrant neuronal gene activation. In mice, deletion of Zic2 impairs NCC delamination, while ZIC2 overexpression in chick embryos at post-migratory neural crest stages elicits ectopic delamination from the neural tube. These findings reveal an essential ARID1A-ZIC2 axis essential for EMT and CNCC delamination.
Paediatric sepsis has a significant global impact and highly heterogeneous clinical presentation. The clinical pathway encompasses recognition, escalation and de-escalation. In each aspect, diagnostics have a fundamental influence over outcomes in children. Biomarkers can aid in creating a larger low-risk group of children from those in the clinical grey area who would otherwise receive antibiotics 'just in case'. Current biomarkers include C reactive protein and procalcitonin, which are limited in their clinical use to guide appropriate and rapid treatment. Biomarker discovery has focused on single biomarkers, which, so far, have not outperformed current biomarkers, as they fail to recognise the complexity of sepsis. The identification of multiple host biomarkers that may form a panel in a clinical test has the potential to recognise the complexity of sepsis and provide improved diagnostic performance. In this review, we discuss novel biomarkers and novel ways of using existing biomarkers in the assessment and management of sepsis along with the significant challenges in biomarker discovery at present. Validation of biomarkers is made less meaningful due to methodological heterogeneity, including variations in sepsis diagnosis, biomarker cut-off values and patient populations. Therefore, the utilisation of platform studies is necessary to improve the efficiency of biomarkers in clinical practice.
A method includes receiving medical image data from an image sharing application running on a sharing device. The method further includes determining a category of medical information represented in the medical image data. The method also includes identifying a viewing device to view the medical image data. The method additionally includes transmitting, to the viewing device, a request for confirmation of a medical condition associated with the category of medical information, wherein the request allows the viewing device to view the medical image data in an image viewing application running on the viewing device before an end of a timeout period. The method further includes receiving, from the viewing device, a signal confirming the medical condition based on the medical image data. The method also includes in response to receiving the signal, transmitting an activation signal to each member user device of a medical team associated with the viewing device.
This will be a single centre prospective observational study. 50 consecutive patients admitted to the surgical intensive care unit (SICU) who are deemed to require cardiac output monitoring by the treating intensivist will be studied. Data collection is planned to be carried out over 2 consecutive years. Inclusion criteria are: 1) Patients who are deemed to require cardiac output monitoring. 2) Patients 21 years old and above. 3) American Society of Anesthesiologist (ASA) physical status 1 to 4. Exclusion criteria are: 1) Patients who are not on mechanical ventilation. 2) Patients who are not in sinus rhythm. 3) Patients with allergy to adhesive tapes. Patients will be treated as per department protocols and no additional intervention will be performed. Each patient will have an arterial catheter inserted as per our usual practice. All patients will have the FloTrac® connected to the arterial catheter (standard of care in CGH SICU) and the NICOM Cheetah® electrodes placed on the skin across the anterior thoracic wall. The FloTrac CO monitor is the current standard of care for cardiac output monitoring in the SICU of CGH. All patients deemed to require cardiac output monitoring will receive the FloTrac (as per departmental practice). The NICOM CO monitor involves the application of non-invasive sensor strips. In this study, it will be applied to patients receiving the FloTrac (standard of care), on top of the standard care of monitoring with Flotrac. For each patient, standard demographic and SICU data (age, gender, comorbidities, ASA score, admission diagnosis, type of surgery, cause of haemodynamic instability, mean arterial pressure (MAP) and central venous pressure (CVP) at the time of instituting cardiac output (CO) monitoring, use of inotropic support, presence of renal replacement therapy, presence of mechanical ventilation and APACHE II score) will be collected. Cardiac Index (CI) values simultaneously recorded by the NICOM Cheetah® and FloTrac® on a 15-minutely basis for the first 10-hour period will also be collected. These data will be automatically recorded by the FloTrac® Vigilance monitor and the Cheetah NICOM monitor and transcribed to a data entering/analysis software by the principal and co-principal investigators for data analysis.
The present disclosure provides an electronic device including a processor and a memory device. The memory device is configured to store a residual neural network group for restoring data and a multi-head neural network. The multi-head neural network contains multiple of self-attention neural modules. The processor is configured to perform the following steps. Multiple pieces of data corresponding to multiple of leads are input into residual neural network groups, respectively, to generate multiple of feature map groups respectively correspond to the leads. The feature map groups are classified to the self-attention neural modules according to labels of the feature map groups.
OBJECTIVES: Pulsed laser treatment of melasma has shown some promising results. To compare the effectiveness and safety of 755-nm picosecond alexandrite laser (PSAL) fitted with diffractive lens array (DLA) versus 1064-nm Q-switched neodynimum:yttrium aluminum garnet laser (QSNYL) for the treatment of melasma.
METHODS: We conducted a randomized, split face controlled, 2-year follow-up study. Each face was divided into two parts, each side receiving three treatments with either PSAL or QSNYL at 1 month intervals. Modified Melasma Area Severity Index scores (mMASI), pain scores, patient satisfaction and adverse events were recorded. In vivo reflectance confocal microscopy (RCM) images were acquired.
RESULTS: Twenty subjects were enrolled and three dropped out. At 6 months, mMASI scores were significantly lower than baseline for QSNYL sides (p = 0.022), with no statistically significant difference between PSAL sides before and after treatment, PSAL sides versus QSNYL sides, or patient satisfaction scores. QSNYL treatment was associated with less pain (p = 0.014). No serious adverse events were reported. In the PSAL sides RCM showed a large number of dendritic melanocytes infiltrated in the dermis at 2 weeks and 4 weeks after treatment. Ten patients (58.82%) reported recurrence or exacerbation at 2-year follow-up with no statistically significant difference between the two lasers.
CONCLUSIONS: QSNYL demonstrated short term clinical efficacy for melasma, but did not provide any additional benefit compared to PSAL with DLA. QSNYL was associated with less pain. There was a high recurrence rate at 2-year follow-up. RCM allowed the detection of cellular changes in melasma lesions.
Subjects in the virtual reality group will perform exercises from a 9 task curriculum, on the daVinci Skills Simulator. These exercises included, camera and clutching, energy switching, peg board, energy dissection, matchboard, ringwalk, suture sponge, and vertical defect suturing. Participants will repeat these tasks all metrics are passed and an overall score is reached based on the performance of our expert robotic surgeons.
PCT No. PCT/RU96/00006 Sec. 371 Date Sep. 6, 1996 Sec. 102(e) Date Sep. 6, 1996 PCT Filed Jan. 4, 1996 PCT Pub. No. WO96/21446 PCT Pub. Date Jul. 18, 1996A pharmaceutical composition having an antialcoholic and nootropic effect which is administered sublingually. The active ingredients of the composition are the amino acid L-threonine or a pharmaceutically acceptable salt thereof and vitamin B6. A method for reducing and eliminating the pathological attraction to alcohol and treatment of alcohol abstinence syndrome, as well as a method for increasing attention comprises sublingual administration of an effective amount of the composition.